Cell Signaling Technology, Astellas Pharma in cancer personalized medicine deal
DANVERS, Mass.—Cell Signaling Technology Inc. (CST) recently announced a joint commercialization partnership with Astellas Pharma Inc. of Tokyo, focused on the delivery of personalized cancer therapeutics and diagnostics. Under this agreement, CST and Astellas have pooled their respective worldwide intellectual property estates relating to the fusion kinase, EML4-ALK, to enable the commercialization of diagnostic and therapeutic products targeting this cancer enzyme. CST will have the sole rights to exploit these joint intellectual property estates in the field of human medical diagnostics worldwide. Astellas will have the sole rights to exploit these joint intellectual property rights in the field of human therapeutics worldwide. Financial terms of the partnership were not disclosed.
"CST is very pleased to see that our focused cancer research efforts and proprietary antibody technology are being applied to the development of next- generation diagnostic and therapeutic products intended to fulfill the promise of personalized cancer medicine. EML4-ALK is currently one of the most promising therapeutic targets for the treatment of non-small cell lung cancer. This agreement with Astellas enables the accelerated development of products targeting EML4-ALK," says Dr. Michael J. Comb, president and CEO of CST.